Curated News
By: NewsRamp Editorial Staff
April 28, 2025
Kairos Pharma to Present New Data on KROS 101 at ASCO Annual Meeting
TLDR
- Kairos Pharma (NYSE American: KAPA) will present new data on KROS 101 at ASCO, enhancing its potential in cancer treatment.
- Kairos utilizes structural biology with ENV105 to target CD105, reversing drug resistance in cancer treatments.
- Kairos' research aims to improve cancer therapy by overcoming drug resistance, offering hope for better treatment outcomes.
- Kairos CEO will share new findings on KROS 101 at ASCO, advancing discussions and knowledge in cancer treatment.
Impact - Why it Matters
This news matters as it highlights the potential of KROS 101 in optimizing cancer treatment, offering hope for overcoming drug resistance and immune suppression in cancer. The presentation at ASCO provides a platform for Kairos Pharma to showcase its innovative approach to addressing unmet medical needs in various cancer types, potentially leading to significant advancements in cancer therapeutics.
Summary
Kairos Pharma (NYSE American: KAPA) announced the presentation of new data on KROS 101, a small molecule GITR ligand agonist, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The poster will discuss the effects of KROS 101 on T effector cells, T reg cells, and intratumoral CD8 T cell cytotoxicity. Kairos CEO John Yu, M.D., emphasized the significance of sharing these findings and advancing discussions on KROS 101's potential in cancer treatment optimization.
About Kairos Pharma Ltd. Kairos Pharma is a leading oncology therapeutics company based in Los Angeles. The company's ENV105, an antibody targeting CD105, is in Phase 2 clinical trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer. ENV105 aims to reverse drug resistance by targeting CD105 and enhancing the effectiveness of standard cancer therapies. For more information, visit www.KairosPharma.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma to Present New Data on KROS 101 at ASCO Annual Meeting
